Psoriasis drug safety checked in kids over years
NCT ID NCT03218488
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 23 times
Summary
This study tracks the long-term safety of the drug ustekinumab in children aged 6 to 17 with moderate to severe plaque psoriasis. Researchers monitor for serious infections, cancers, and autoimmune problems, as well as effects on growth and puberty. About 135 kids are being observed over time to ensure the drug remains safe for ongoing use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Andreas Sygros Hospital
Athens, 16121, Greece
-
Bispebjerg Hospital
Copenhagen, NV 2400, Denmark
-
CH Victor Dupouy Argenteuil
Argenteuil, 95107, France
-
CHRU Besancon Hopital Jean Minjoz
Besançon, 25030, France
-
CHU Saint Etienne Hopital Nord
Saint-Etienne, 42055, France
-
CHU de Liège - Domaine Universitaire du Sart Tilman
Liège, 4000, Belgium
-
FSBI 'Scientific Centre of Children Health' of the Russian Academy of Medical Sciences
Moscow, 119991, Russia
-
Gemeinschaftspraxis Dres. Quist
Mainz, 55128, Germany
-
Gentofte Herlev Hospital
Hellerup, 2800, Denmark
-
Grand Hôpital de Charleroi
Loverval, 6280, Belgium
-
Great Ormond Street Hospital
London, WC1N 3JH, United Kingdom
-
Groupe Hospitalier Pellegrin CHU de Bordeaux
Bordeaux, 33076, France
-
Hopital Necker Enfants Malades
Paris, 75743, France
-
ICH Hopital A. Morvan
Brest, 29609, France
-
Kinderspital Zürich
Zurich, 8032, Switzerland
-
Le Bateau Blanc
Martigues, 13500, France
-
Llc Ultramed
Omsk, 644024, Russia
-
Moscow Research-Practical Center of Dermatovenerology and Cosmetology
Moscow, 119049, Russia
-
Oslo universitetssykehus HF, Rikshospitalet
Oslo, 0027, Norway
-
Praxis Dr. med. Beate Schwarz - Germany
Langenau, 89129, Germany
-
Radboudumc
Nijmegen, 6525 EX, Netherlands
-
Saint-Petersburg State Pediatric Medical Academy of RosZdrav
Saint Petersburg, 194353, Russia
-
Salford Royal Hospital
Salford, M6 8HD, United Kingdom
-
UCL Hopital Saint-Luc
Brussels, 1200, Belgium
-
UZ Leuven
Leuven, 3000, Belgium
-
Uniklinik Graz
Graz, 8036, Austria
-
Universitatsmedizin der Johannes Gutenberg Universitat Mainz
Mainz, 55131, Germany
-
University Hospital for Skin and Venereal Diseases
Thessaloniki, 54 643, Greece
-
University Hospital of Wales
Cardiff, CF14 4XW, United Kingdom
-
Whipps Cross University Hospital
London, E11 1NR, United Kingdom
Conditions
Explore the condition pages connected to this study.